FR13C0061I1 - - Google Patents

Info

Publication number
FR13C0061I1
FR13C0061I1 FR13C0061C FR13C0061I1 FR 13C0061 I1 FR13C0061 I1 FR 13C0061I1 FR 13C0061 C FR13C0061 C FR 13C0061C FR 13C0061 I1 FR13C0061 I1 FR 13C0061I1
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
Other languages
French (fr)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32329647&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR13C0061(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of FR13C0061I1 publication Critical patent/FR13C0061I1/fr
Application granted granted Critical
Publication of FR13C0061I2 publication Critical patent/FR13C0061I2/fr
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/58—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems with hetero atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
FR13C0061C 2002-11-20 2013-11-12 Composes 4-oxoquinolines et leur utilisation comme inhibiteurs du hiv-integrase Active FR13C0061I2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2002336843 2002-11-20
JP2003065807 2003-03-11
JP2003139616 2003-05-16
PCT/JP2003/014773 WO2004046115A1 (ja) 2002-11-20 2003-11-20 ４−オキソキノリン化合物及びそのｈｉｖインテグラーゼ阻害剤としての利用

Publications (2)

Publication Number Publication Date
FR13C0061I1 true FR13C0061I1 (enExample) 2013-12-20
FR13C0061I2 FR13C0061I2 (fr) 2014-11-07

Family

ID=32329647

Family Applications (1)

Application Number Title Priority Date Filing Date
FR13C0061C Active FR13C0061I2 (fr) 2002-11-20 2013-11-12 Composes 4-oxoquinolines et leur utilisation comme inhibiteurs du hiv-integrase

Country Status (31)

Country Link
US (6) US7176220B2 (enExample)
EP (5) EP2161258A3 (enExample)
KR (1) KR100665919B1 (enExample)
AR (2) AR042095A1 (enExample)
AT (1) ATE443048T1 (enExample)
AU (1) AU2003302029B8 (enExample)
BE (1) BE2013C063I2 (enExample)
BR (1) BRPI0306214B1 (enExample)
CA (1) CA2470365C (enExample)
CY (2) CY1110690T1 (enExample)
CZ (1) CZ2004764A3 (enExample)
DE (1) DE60329318D1 (enExample)
DK (1) DK1564210T5 (enExample)
ES (1) ES2329240T3 (enExample)
FR (1) FR13C0061I2 (enExample)
HU (1) HUS1300066I1 (enExample)
IL (2) IL162548A0 (enExample)
LT (1) LTPA2013018I1 (enExample)
LU (1) LU92307I2 (enExample)
MX (1) MXPA04006553A (enExample)
MY (1) MY136173A (enExample)
NO (3) NO327098B1 (enExample)
NZ (1) NZ533641A (enExample)
PE (1) PE20040840A1 (enExample)
PT (1) PT1564210E (enExample)
SI (1) SI1564210T1 (enExample)
SK (1) SK2662004A3 (enExample)
TR (1) TR200401663T1 (enExample)
TW (1) TWI248928B (enExample)
WO (1) WO2004046115A1 (enExample)
ZA (1) ZA200404537B (enExample)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1441735T1 (sl) 2001-10-26 2006-06-30 Angeletti P Ist Richerche Bio N-substituirani hidroksipirimidinon-karboksamidniinhibitorji HIV-integraze
BRPI0306214B1 (pt) * 2002-11-20 2017-08-08 Japan Tobacco Inc. 4-oxoquinoline compound and use of this as a hiv integrase inhibitor
ATE482208T1 (de) * 2004-03-10 2010-10-15 Us Of America Represented By T Chinolin-4-one als inhibitoren der retroviralen integrase zur behandlung von hiv, aids und aids- related complex (arc)
WO2005113509A1 (en) * 2004-05-20 2005-12-01 Japan Tobacco Inc. Novel 4-oxoquinoline compound and use thereof as hiv integrase inhibitor
MY134672A (en) * 2004-05-20 2007-12-31 Japan Tobacco Inc Stable crystal of 4-oxoquinoline compound
EP3287130A1 (en) * 2004-05-21 2018-02-28 Japan Tobacco Inc. Combinations comprising a 4-isoquinolone derivative and protease inhibitors
US7745459B2 (en) 2004-09-21 2010-06-29 Japan Tobacco Inc. Quinolizinone compound and use thereof as HIV integrase inhibitor
WO2006033422A1 (ja) * 2004-09-21 2006-03-30 Japan Tobacco Inc. キノリジノン化合物、およびそのｈｉｖインテグラーゼ阻害剤としての利用
UA87884C2 (uk) * 2004-12-03 2009-08-25 Мерк Энд Ко., Инк. Безводна кристалічна калієва сіль інгібітора віл-інтегрази
US7772191B2 (en) 2005-05-10 2010-08-10 Boehringer Ingelheim International Gmbh Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
US20070032522A1 (en) * 2005-07-01 2007-02-08 Kumar Dange V Antiviral agents
WO2007063869A1 (ja) * 2005-11-30 2007-06-07 Japan Tobacco Inc. 高純度キノロン化合物の製造方法
US20090233964A1 (en) * 2005-12-30 2009-09-17 Gilead Sciences, Inc. Methods for improving the pharmacokinetics of hiv integrase inhibitors
KR101524165B1 (ko) * 2005-12-30 2015-06-01 길리애드 사이언시즈, 인코포레이티드 Ｈｉｖ 인테그라제 억제제의 약동학을 개선하기 위한 방법
AU2013203476C1 (en) * 2005-12-30 2016-11-17 Gilead Sciences, Inc. Methods for improving the pharmacokinetics of hiv integrase inhibitors
US20090018162A1 (en) * 2006-02-01 2009-01-15 Yuji Matsuzaki Use of 6-(3-chloro-2-fluorobenzyl)-1-[(2s)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid or salt thereof for treating retrovirus infection
WO2007092802A1 (en) * 2006-02-09 2007-08-16 Boehringer Ingelheim International Gmbh Method for treating hiv infection through co-administration of tipranavir and gs 9137
ES2531190T3 (es) * 2006-03-06 2015-03-11 Japan Tobacco Inc Método para producir un compuesto de 4-oxoquinolina
WO2007102499A1 (ja) * 2006-03-06 2007-09-13 Japan Tobacco Inc. ４－オキソキノリン化合物の製造方法
PE20080697A1 (es) 2006-05-03 2008-08-05 Boehringer Ingelheim Int Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion
RU2399616C1 (ru) * 2006-06-23 2010-09-20 Джапан Тобакко Инк. Производное 6-(гетероциклзамещенный бензил)-4-оксохинолина и его применение в качестве ингибитора интегразы вич
TW200811153A (en) * 2006-06-23 2008-03-01 Japan Tobacco Inc 6-(heterocyclyl-substituted benzyl)-4-oxoquinoline compound and use thereof as HIV integrase inhibitor
SI2049506T2 (sl) 2006-07-07 2024-07-31 Gilead Sciences, Inc. Modulatorji farmakokinetičnih lastnosti terapevtikov
MX2009000661A (es) * 2006-07-19 2009-03-27 Univ Georgia Res Found Piridinon-diceto-acidos: inhibidores de replicacion de vih en terapia de combinacion.
HRP20090213B1 (hr) * 2006-09-12 2016-12-02 Gilead Sciences, Inc. Postupak i međuprodukti u pripravi inhibitora integraze
EA016267B1 (ru) 2006-09-29 2012-03-30 Айденикс Фармасьютикалз, Инк. Энантиомерно чистые фосфоиндолы в качестве ингибиторов hiv
EP2269992A1 (en) 2006-12-22 2011-01-05 Avexa Limited Bicyclic pyrimidinones for the treatment of viral infections
ES2779826T3 (es) * 2007-02-23 2020-08-20 Gilead Sciences Inc Moduladores de propiedades farmacocinéticas de agentes terapéuticos
CN103356622A (zh) * 2007-06-29 2013-10-23 吉里德科学公司 治疗用组合物及其用途
CN101686972B (zh) * 2007-06-29 2013-08-14 吉里德科学公司 治疗用组合物和方法
CL2008002427A1 (es) 2007-08-16 2009-09-11 Boehringer Ingelheim Int Composicion farmaceutica que comprende 1-cloro-4-(b-d-glucopiranos-1-il)-2-[4-((s)-tetrahidrofurano-3-iloxi)bencil]-benceno combinado con 1-[(4-metilquinazolin-2-il)metil]-3-metil-7-(2-butin-1-il)-8-(3-(r)-aminopiperidin-1-il)xantina; y su uso para tratar diabetes mellitus tipo 2.
AR068403A1 (es) * 2007-09-11 2009-11-18 Gilead Sciences Inc Proceso e intermediarios para la preparacion de inhibidores de integrasa
EP2197847B1 (en) * 2007-09-12 2012-11-07 Concert Pharmaceuticals Inc. Deuterated 4 -oxoquinoline derivative for the treatment of hiv infection
ATE541841T1 (de) * 2007-11-15 2012-02-15 Boehringer Ingelheim Int Inhibitoren der replikation des human immunodeficiency virus
WO2009062285A1 (en) 2007-11-16 2009-05-22 Boehringer Ingelheim International Gmbh Inhibitors of human immunodeficiency virus replication
EP2234608A2 (en) 2007-12-11 2010-10-06 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitors using metal binding moieties in combination with targeting moieties
WO2009089263A2 (en) * 2008-01-07 2009-07-16 Ardea Biosciences Inc. Novel compositions and methods of use
MX342377B (es) 2008-05-02 2016-09-27 Gilead Sciences Inc Uso de particulas trasportadoras solidas para mejorar la capacidad de procesamiento de un agente farmaceutico.
WO2010073078A2 (en) * 2008-12-22 2010-07-01 Orchid Research Laboratories Ltd. Heterocyclic compounds as hdac inhibitors
KR101645759B1 (ko) * 2009-02-06 2016-08-04 길리애드 사이언시즈, 인코포레이티드 조합 요법용 정제
SG173619A1 (en) 2009-02-13 2011-09-29 Boehringer Ingelheim Int Pharmaceutical composition comprising a sglt2 inhibitor, a dpp-iv inhibitor and optionally a further antidiabetic agent and uses thereof
WO2010137032A2 (en) 2009-05-14 2010-12-02 Matrix Laboratories Ltd. Novel polymorphic forms of elvitegravir and its pharmaceutically acceptable salts
WO2011004389A2 (en) 2009-06-18 2011-01-13 Matrix Laboratories Ltd An improved process for the preparation of elvitegravir
EP2470014A4 (en) * 2009-08-26 2013-01-16 Merck Sharp & Dohme HIV integrase inhibitors
WO2011039108A2 (en) 2009-09-30 2011-04-07 Boehringer Ingelheim International Gmbh Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives
EA020798B1 (ru) 2009-09-30 2015-01-30 Бёрингер Ингельхайм Интернациональ Гмбх СПОСОБ ПОЛУЧЕНИЯ КРИСТАЛЛИЧЕСКОЙ ФОРМЫ 1-ХЛОР-4-(β-D-ГЛЮКОПИРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГИДРОФУРАН-3-ИЛОКСИ)БЕНЗИЛ]БЕНЗОЛА
US10610489B2 (en) 2009-10-02 2020-04-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof
AU2010305805B2 (en) 2009-10-13 2014-04-03 Elanco Animal Health Ireland Limited Macrocyclic integrase inhibitors
SG181524A1 (en) 2009-12-07 2012-07-30 Univ Georgia Pyridinone hydroxycyclopentyl carboxamides: hiv integrase inhibitors with therapeutic applications
WO2011121105A1 (en) 2010-04-02 2011-10-06 Tibotec Pharmaceuticals Macrocyclic integrase inhibitors
DE102010021637A1 (de) 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
EP2588450B1 (en) 2010-07-02 2017-05-24 Gilead Sciences, Inc. Napht-2-ylacetic acid derivatives to treat aids
SG186821A1 (en) 2010-07-02 2013-02-28 Gilead Sciences Inc 2 -quinolinyl- acetic acid derivatives as hiv antiviral compounds
UY33937A (es) 2011-03-07 2012-09-28 Boehringer Ingelheim Int Composiciones farmacéuticas que contienen inhibidores de dpp-4 y/o sglt-2 y metformina
SG194512A1 (en) 2011-04-21 2013-12-30 Gilead Sciences Inc Benzothiazole compounds and their pharmaceutical use
WO2013103724A1 (en) 2012-01-04 2013-07-11 Gilead Sciences, Inc. 2- (tert - butoxy) -2- (7 -methylquinolin- 6 - yl) acetic acid derivatives for treating aids
WO2013103738A1 (en) 2012-01-04 2013-07-11 Gilead Sciences, Inc. Napthalene acetic acid derivatives against hiv infection
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
US9192617B2 (en) 2012-03-20 2015-11-24 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
CA2850881C (en) 2012-04-20 2021-02-16 Gilead Sciences, Inc. Benzothiazol-6-yl acetic acid derivatives and their use for treating an hiv infection
AU2013296289B2 (en) 2012-08-03 2017-10-05 Gilead Sciences, Inc. Process and intermediates for preparing integrase inhibitors
CZ304983B6 (cs) 2012-10-12 2015-03-11 Zentiva, K.S. Způsob výroby a nové intermediáty syntézy elvitegraviru
CZ304984B6 (cs) 2012-10-12 2015-03-11 Zentiva, K.S. Zlepšený způsob výroby a nové intermediáty syntézy elvitegraviru
SI3067358T1 (sl) 2012-12-21 2019-12-31 Gilead Sciences, Inc. Policiklične spojine karbamoilpiridona in njihova farmacevtska uporaba
AU2013370517B2 (en) 2012-12-26 2017-04-06 Société des Produits Nestlé S.A. Low density coated animal litter compositions
HK1213818A1 (zh) 2013-04-05 2016-07-15 勃林格殷格翰国际有限公司 依帕列净的治疗用途
PT2981271T (pt) 2013-04-05 2019-02-19 Boehringer Ingelheim Int Utilizações terapêuticas de empagliflozina
CA2812519A1 (en) 2013-04-05 2014-10-05 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US11813275B2 (en) 2013-04-05 2023-11-14 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
SI2986304T1 (sl) 2013-04-18 2022-04-29 Boehringer Ingelheim International Gmbh Farmacevtski sestavek, postopki za zdravljenje in njegove uporabe
CZ307255B6 (cs) 2013-07-11 2018-05-02 Zentiva, K.S. Nový způsob přípravy elvitegraviru
AU2014286993B2 (en) 2013-07-12 2018-10-25 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their use for the treatment of HIV infections
NO2865735T3 (enExample) 2013-07-12 2018-07-21
NO2717902T3 (enExample) 2014-06-20 2018-06-23
TWI744723B (zh) 2014-06-20 2021-11-01 美商基利科學股份有限公司 多環型胺甲醯基吡啶酮化合物之合成
TW201613936A (en) 2014-06-20 2016-04-16 Gilead Sciences Inc Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
WO2016081464A1 (en) * 2014-11-17 2016-05-26 Nirogyone Therapeutics, Inc. Monocarboxylate transport modulators and uses thereof
TWI695003B (zh) 2014-12-23 2020-06-01 美商基利科學股份有限公司 多環胺甲醯基吡啶酮化合物及其醫藥用途
CA2980362C (en) 2015-04-02 2020-02-25 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
WO2016193997A2 (en) * 2015-06-03 2016-12-08 Msn Laboratories Private Limited Process for the preparation of 6-(3-chloro-2-fluorobenzyl)-1-[(2s)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid and pharmaceutically acceptable salts thereof
US10881077B2 (en) 2015-10-23 2021-01-05 Société des Produits Nestlé S.A. Low density pet litters and methods of making such pet litters
RU2654062C2 (ru) * 2016-07-14 2018-05-16 Государственное бюджетное образовательное учреждение высшего профессионального образования "Волгоградский государственный медицинский университет" Министерства здравоохранения Российской Федерации Производные хиназолин-4(3н)-она, ингибирующие натрий-водородный обмен
CN109922813A (zh) 2016-11-10 2019-06-21 勃林格殷格翰国际有限公司 药物组合物、治疗方法及其用途

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3472859A (en) * 1966-11-01 1969-10-14 Sterling Drug Inc 1-alkyl-1,4-dihydro-4-oxo-3 quinoline-carboxylic acids and esters
JPS4826772A (enExample) 1971-08-11 1973-04-09
DE3501247A1 (de) 1985-01-16 1986-07-17 Bayer Ag, 5090 Leverkusen Aminoacrylsaeure-derivate
US5563138A (en) * 1987-04-16 1996-10-08 Otsuka Pharmaceutical Company, Limited Benzoheterocyclic compounds
NO885426L (no) * 1987-12-11 1989-06-12 Dainippon Pharmaceutical Co Kinolinderivater, samt fremgangsmaate ved fremstilling derav.
US4920120A (en) * 1988-01-25 1990-04-24 Warner-Lambert Company Antibacterial agents
DE3934082A1 (de) * 1989-10-12 1991-04-18 Bayer Ag Chinoloncarbonsaeurederivate, verfahren zu ihrer herstellung sowie ihre verwendung als antivirale mittel
DE4015299A1 (de) * 1990-05-12 1991-11-14 Bayer Ag Verfahren zur herstellung von 3-amino-2-(het)-aroyl-acrylsaeurederivaten
IL100555A (en) 1991-02-07 2000-08-31 Hoechst Marion Roussel Inc N-substituted quinoline derivatives their preparation their use for the preparation of medicaments and the pharmaceutical compositions containing them
NO304832B1 (no) 1992-05-27 1999-02-22 Ube Industries Aminokinolonderivater samt middel mot HIV
JP2993316B2 (ja) 1992-05-27 1999-12-20 宇部興産株式会社 アリール基又は複素芳香環基置換アミノキノロン誘導体及びエイズ治療剤
JPH06199635A (ja) 1992-12-28 1994-07-19 Kanebo Ltd 化粧料
JPH06199835A (ja) 1993-01-08 1994-07-19 Hokuriku Seiyaku Co Ltd ８−ジフルオロメトキシキノリン−３−カルボン酸誘導体
JPH06271568A (ja) 1993-03-22 1994-09-27 Hokuriku Seiyaku Co Ltd ７−フェニルピペラジニルキノリン−３−カルボン酸誘導体
CN1147248A (zh) 1994-04-28 1997-04-09 山之内制药株式会社 N-(3-吡咯烷基)苯甲酰胺衍生物
NZ287550A (en) * 1994-07-18 1998-01-26 Ube Industries 8-trifluoromethylquinolinecarboxylic acid derivatives; medicaments
JP2930539B2 (ja) 1994-07-18 1999-08-03 三共株式会社 トリフルオロメチルキノリンカルボン酸誘導体
JPH08183776A (ja) 1994-12-28 1996-07-16 Hideaki Yamaguchi 金属の表面保護剤ならびにそれを用いた製造方法
US6303611B1 (en) * 1996-03-08 2001-10-16 Adolor Corporation Kappa agonist compounds and pharmaceutical formulations thereof
ES2171260T3 (es) 1996-04-12 2002-09-01 Us Gov Health & Human Serv Compuestos derivados de acridona utiles como agentes antineoplasicos y antirretroviricos.
US6287550B1 (en) * 1996-12-17 2001-09-11 The Procter & Gamble Company Animal care system and litter with reduced malodor impression
US5989451A (en) 1997-02-07 1999-11-23 Queen's University At Kingston Compounds and methods for doping liquid crystal hosts
FR2761687B1 (fr) 1997-04-08 2000-09-15 Centre Nat Rech Scient Derives de quinoleines, possedant notamment des proprietes antivirales, leurs preparations et leurs applications biologiques
JP3776203B2 (ja) 1997-05-13 2006-05-17 第一製薬株式会社 Ｉｃａｍ−１産生阻害剤
KR20010013377A (ko) * 1997-06-04 2001-02-26 데이비드 엠 모이어 마일드한 잔류성 항균 조성물
TW527355B (en) 1997-07-02 2003-04-11 Bristol Myers Squibb Co Inhibitors of farnesyl protein transferase
JPH1184556A (ja) 1997-09-08 1999-03-26 Konica Corp ハロゲン化銀乳剤、該乳剤を用いる感光材料の処理方法及び撮影方法
GB9721964D0 (en) 1997-10-16 1997-12-17 Pfizer Ltd Isoquinolines
GB9807903D0 (en) 1998-04-14 1998-06-10 Smithkline Beecham Plc Novel compounds
US6399629B1 (en) * 1998-06-01 2002-06-04 Microcide Pharmaceuticals, Inc. Efflux pump inhibitors
US6248736B1 (en) 1999-01-08 2001-06-19 Pharmacia & Upjohn Company 4-oxo-1,4-dihydro-3-quinolinecarboxamides as antiviral agents
US6248739B1 (en) 1999-01-08 2001-06-19 Pharmacia & Upjohn Company Quinolinecarboxamides as antiviral agents
FR2795726A1 (fr) 1999-06-30 2001-01-05 Aventis Cropscience Sa Nouveaux pyrazoles fongicides
DE19950898A1 (de) * 1999-10-22 2001-04-26 Aventis Pharma Gmbh Heterocyclisch substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
PE20011349A1 (es) 2000-06-16 2002-01-19 Upjohn Co 1-aril-4-oxo-1,4-dihidro-3-quinolincarboxamidas como agentes antivirales
US6730682B2 (en) 2000-07-12 2004-05-04 Pharmacia & Upjohn Company Heterocycle carboxamides as antiviral agents
US6559145B2 (en) 2000-07-12 2003-05-06 Pharmacia & Upjohn Company Heterocycle carboxamides as antiviral agents
JP2004517860A (ja) 2000-10-12 2004-06-17 メルク　エンド　カムパニー　インコーポレーテッド Ｈｉｖインテグラーゼ阻害薬として有用なアザ−およびポリアザ−ナフタレニルカルボキサミド類
EP1333831A2 (en) 2000-10-12 2003-08-13 Merck & Co., Inc. Aza-and polyaza-naphthalenyl ketones useful as hiv integrase inhibitors
MXPA03005338A (es) * 2000-12-14 2003-10-06 Procter & Gamble Etapa de ciclizacion en el procedimiento de elaboracion de quinolonas y naftiridinas.
WO2002076939A2 (en) 2001-02-05 2002-10-03 Exegenics Inc. Cysteine protease inhibitors
PL365027A1 (en) 2001-03-01 2004-12-27 Shionogi & Co, Ltd. Nitrogen-containing heteroaryl compounds having hiv integrase inhibitory activity
JP4518302B2 (ja) 2001-03-19 2010-08-04 日本化薬株式会社 水溶性ジスアゾ化合物、水性ブラックインク組成物および着色体
JP2002293745A (ja) 2001-03-29 2002-10-09 St Marianna Univ School Of Medicine 慢性関節リウマチ治療剤
JP3980842B2 (ja) 2001-05-11 2007-09-26 バブコック日立株式会社 アンモニア含有排水の浄化装置および浄化方法
JP2003065807A (ja) 2001-08-29 2003-03-05 Mitsubishi Electric Corp プロセスデータのトレンド表示方法および装置
JP3913037B2 (ja) 2001-10-30 2007-05-09 三菱電機株式会社 赤外線検出器
TW200300349A (en) 2001-11-19 2003-06-01 Sankyo Co A 4-oxoqinoline derivative
BRPI0306214B1 (pt) * 2002-11-20 2017-08-08 Japan Tobacco Inc. 4-oxoquinoline compound and use of this as a hiv integrase inhibitor
JP2004253231A (ja) 2003-02-20 2004-09-09 Pioneer Electronic Corp プラズマディスプレイパネル
WO2005113509A1 (en) * 2004-05-20 2005-12-01 Japan Tobacco Inc. Novel 4-oxoquinoline compound and use thereof as hiv integrase inhibitor
MY134672A (en) * 2004-05-20 2007-12-31 Japan Tobacco Inc Stable crystal of 4-oxoquinoline compound
EP3287130A1 (en) * 2004-05-21 2018-02-28 Japan Tobacco Inc. Combinations comprising a 4-isoquinolone derivative and protease inhibitors
WO2007102499A1 (ja) 2006-03-06 2007-09-13 Japan Tobacco Inc. ４－オキソキノリン化合物の製造方法
ES2531190T3 (es) 2006-03-06 2015-03-11 Japan Tobacco Inc Método para producir un compuesto de 4-oxoquinolina
TW200811153A (en) * 2006-06-23 2008-03-01 Japan Tobacco Inc 6-(heterocyclyl-substituted benzyl)-4-oxoquinoline compound and use thereof as HIV integrase inhibitor
HRP20090213B1 (hr) 2006-09-12 2016-12-02 Gilead Sciences, Inc. Postupak i međuprodukti u pripravi inhibitora integraze
AR068403A1 (es) 2007-09-11 2009-11-18 Gilead Sciences Inc Proceso e intermediarios para la preparacion de inhibidores de integrasa
EP2197847B1 (en) * 2007-09-12 2012-11-07 Concert Pharmaceuticals Inc. Deuterated 4 -oxoquinoline derivative for the treatment of hiv infection
WO2009089263A2 (en) 2008-01-07 2009-07-16 Ardea Biosciences Inc. Novel compositions and methods of use
SI23420A (sl) 2010-07-22 2012-01-31 Institut "Jožef Stefan" Kostni vsadki z večslojno prevleko in postopek njihove priprave
US11347056B2 (en) 2018-08-22 2022-05-31 Microsoft Technology Licensing, Llc Foveated color correction to improve color uniformity of head-mounted displays
JP7397852B2 (ja) 2018-08-23 2023-12-13 エルジー イノテック カンパニー リミテッド センシング装置
WO2020040561A1 (ko) 2018-08-24 2020-02-27 한온시스템 주식회사 차량용 공조장치

Also Published As

Publication number Publication date
CA2470365C (en) 2011-05-17
NZ533641A (en) 2006-07-28
BRPI0306214B1 (pt) 2017-08-08
US20050239819A1 (en) 2005-10-27
US20200101061A1 (en) 2020-04-02
SK2662004A3 (sk) 2005-06-02
HK1080852A1 (en) 2006-05-04
NO327098B1 (no) 2009-04-20
EP1564210B9 (en) 2010-03-31
IL162548A (en) 2008-12-29
LTPA2013018I1 (lt) 2022-09-12
MY136173A (en) 2008-08-29
KR20040081443A (ko) 2004-09-21
CY1110690T1 (el) 2015-06-10
US20230190730A1 (en) 2023-06-22
CY2013043I1 (el) 2020-05-29
EP2272516A2 (en) 2011-01-12
EP2272516A3 (en) 2011-03-16
FR13C0061I2 (fr) 2014-11-07
PT1564210E (pt) 2009-10-26
PE20040840A1 (es) 2004-12-30
TR200401663T1 (tr) 2005-04-21
AR042095A1 (es) 2005-06-08
NO20043004L (no) 2004-07-14
DK1564210T3 (da) 2009-11-16
US20150174117A1 (en) 2015-06-25
EP1564210A4 (en) 2007-08-22
ZA200404537B (en) 2005-08-31
CZ2004764A3 (cs) 2005-02-16
KR100665919B1 (ko) 2007-03-08
MXPA04006553A (es) 2004-10-04
BR0306214A (pt) 2004-08-24
HUS1300066I1 (hu) 2016-11-28
EP4059923A1 (en) 2022-09-21
DE60329318D1 (de) 2009-10-29
US20060217413A1 (en) 2006-09-28
US20130172344A1 (en) 2013-07-04
ATE443048T1 (de) 2009-10-15
EP3406596A1 (en) 2018-11-28
EP1564210A1 (en) 2005-08-17
SI1564210T1 (sl) 2010-01-29
IL162548A0 (en) 2005-11-20
NO2013015I2 (no) 2014-06-02
EP2161258A3 (en) 2010-04-07
LU92307I9 (enExample) 2019-01-17
AR087046A2 (es) 2014-02-12
EP2161258A2 (en) 2010-03-10
AU2003302029A1 (en) 2004-06-15
NO2013015I1 (no) 2013-11-07
TW200412339A (en) 2004-07-16
EP1564210B1 (en) 2009-09-16
US8232401B2 (en) 2012-07-31
AU2003302029B8 (en) 2006-08-17
NO2022032I1 (no) 2022-07-22
US7176220B2 (en) 2007-02-13
LU92307I2 (fr) 2014-01-13
ES2329240T3 (es) 2009-11-24
CA2470365A1 (en) 2004-06-03
BRPI0306214B8 (enExample) 2021-05-25
WO2004046115A1 (ja) 2004-06-03
DK1564210T5 (da) 2010-05-03
TWI248928B (en) 2006-02-11
BE2013C063I2 (enExample) 2023-03-07
AU2003302029B2 (en) 2006-08-10

Similar Documents

Publication Publication Date Title
BE2019C547I2 (enExample)
BE2019C510I2 (enExample)
BE2018C021I2 (enExample)
BE2017C049I2 (enExample)
BE2017C005I2 (enExample)
BE2016C069I2 (enExample)
BE2016C040I2 (enExample)
BE2016C013I2 (enExample)
BE2015C078I2 (enExample)
BE2016C002I2 (enExample)
BE2018C018I2 (enExample)
BE2015C017I2 (enExample)
BE2014C053I2 (enExample)
BE2014C051I2 (enExample)
BE2014C041I2 (enExample)
BE2014C030I2 (enExample)
BE2014C016I2 (enExample)
BE2014C015I2 (enExample)
BE2013C063I2 (enExample)
BE2013C039I2 (enExample)
BE2011C038I2 (enExample)
BE2015C068I2 (enExample)
BE2013C046I2 (enExample)
BR0315835A2 (enExample)
AU2001279184A1 (enExample)